Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Spreafico, Anna; Oza, Amit M.; Clarke, Blaise A.; Mackay, Helen; Shaw, Patricia; Butler, Marcus O.; Dhani, Neesha C.; Lheureux, Stéphanie; Wilson, Michelle; Welch, Stephen; Zhang, T.; Yu, Celeste; Stockley, Tracy L.; Siu, Lillian L.; Kamel‐Reid, Suzanne; Bedard, Philippe L.

doi:10.1016/j.ygyno.2016.12.002

Cited by 29 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advancements in genomic and proteomic approaches have improved methods for the identification of candidate biomarkers and helped to develop effective screening strategies for early detection [5]. Molecular profiling and individualized OC treatment have provided optimism regarding the role of individualized medicine for oncological patients [6].…”

Section: Introductionmentioning

confidence: 99%

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Wilczyński

Paradowska

2020

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the leading causes of cancer death in women, with high-grade serous ovarian cancer (HGSOC) being the most lethal gynecologic malignancy among women. This high fatality rate is the result of diagnosis of a high number of new cases when cancer implants have already spread. The poor prognosis is due to our inadequate understanding of the molecular mechanisms preceding ovarian malignancy. Knowledge about the site of origination has been improved recently by the discovery of tube intraepithelial cancer (TIC), but the potential risk factors are still obscure. Due to high tumoral heterogeneity in OC, the establishment of early stage biomarkers is still underway. Microbial infection may induce or result in chronic inflammatory infection and in the pathogenesis of cancers. Microbiome research has shed light on the relationships between the host and microbiota, as well as the direct roles of host pathogens in cancer development, progression, and drug efficacy. While controversial, the detection of viruses within ovarian malignancies and fallopian tube tissues suggests that these pathogens may play a role in the development of OC. Genomic and proteomic approaches have enhanced the methods for identifying candidates in early screening. This article summarizes the existing knowledge related to the molecular mechanisms that lead to tumorigenesis in the ovary, as well as the viruses detected in OC cases and how they may elevate this process.

show abstract

Section: Introductionmentioning

confidence: 99%

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Wilczyński

Paradowska

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Firstly, we identified potential targetable genomic mutations in CCC using an extensive literature search (24,25). Patients with CCC (64%) had ≥1 somatic mutation (24).…”

Section: Candidate Mutated Genes For Enhancing the Therapeutic Ratio mentioning

confidence: 99%

“…Patients with CCC (64%) had ≥1 somatic mutation (24). These included ARID1A; PIK3CA; PTEN; KRAS proto-oncogene, GTPase (KRAS); NRAS proto-oncogene, GTPase; B-Raf proto-oncogene, serine/threonine kinase (BRAF); zincfinger protein 217; AKT serine/threonine kinase (AKT); TP53; Wnt/β-catenin (CTNNB1); microsatellite instability; mutL homolog 1; SRC proto-oncogene, non-receptor tyrosine kinase; ETS proto-oncogene 1, transcription factor; protein kinase DNA-activated, catalytic polypeptide; APC membrane recruitment protein 1; AT-rich interaction domain 2; B cell CLL/lymphoma 11A; CREB binding protein; erb-b2 receptor tyrosine kinase 2 (ERBB2); exostosin glycosyltransferase 1; Fanconi anemia complementation group D2; mutS homolog 6 (MSH6), neurofibromin 1 (NF1); notch 1 (NOTCH1), nuclear mitotic apparatus protein 1; phosphodiesterase 4D interacting protein; protein phosphatase 2 scaffold subunit Aalpha (PPP2R1A); ring finger protein 213; spectrin repeat containing nuclear envelope protein 1; CUB and Sushi multiple domains 3; latrophilin 3; LDL receptor related protein 1B; speckle type BTB/POZ protein (SPOP); speckle type BTB/POZ protein (KMT2D) and TP53 (21,(24)(25)(26)(27). The genetic mutations related to chromatin remodeling, DNA repair signaling, PI3K-AKT-mTOR, Notch signaling and CTNNB1 pathway may be involved in CCC biology (27).…”

Section: Candidate Mutated Genes For Enhancing the Therapeutic Ratio mentioning

confidence: 99%

Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Inhibitors of poly(ADP-ribose) polymerase (PARP) are new types of personalized treatment of relapsed platinum-sensitive ovarian cancer harboring BRCA1/2 mutations. Ovarian clear cell cancer (CCC), a subset of ovarian cancer, often appears as low-stage disease with a higher incidence among Japanese. Advanced CCC is highly aggressive with poor patient outcome. The aim of the present study was to determine the potential synthetic lethality gene pairs for PARP inhibitions in patients with CCC through virtual and biological screenings as well as clinical studies. We conducted a literature review for putative PARP sensitivity genes that are associated with the CCC pathophysiology. Previous studies identified a variety of putative target genes from several pathways associated with DNA damage repair, chromatin remodeling complex, PI3K-AKT-mTOR signaling, Notch signaling, cell cycle checkpoint signaling, BRCA-associated complex and Fanconi's anemia susceptibility genes that could be used as biomarkers or therapeutic targets for PARP inhibition. BRCA1/2, ATM, ATR, BARD1, CCNE1, CHEK1, CKS1B, DNMT1, ERBB2, FGFR2, MRE11A, MYC, NOTCH1 and PTEN were considered as candidate genes for synthetic lethality gene partners for PARP interactions. When considering the biological background underlying PARP inhibition, we hypothesized that PARP inhibitors would be a novel synthetic lethal therapeutic approach for CCC tumors harboring homologous recombination deficiency and activating oncogene mutations. The results showed that the majority of CCC tumors appear to have indicators of DNA repair dysfunction similar to those in BRCA-mutation carriers, suggesting the possible utility of PARP inhibitors in a subset of CCC.

show abstract

“…Those retrospective, yet to be validated analyses have generated hypotheses that have to be evaluated prospectively to be proven clinically useful. Currently, profiling objectives are toward the identification and validation of biomarkers in prospective clinical trials . With advancing technology, costs should become less prohibitive and may be augmented by the development of customized, subtype‐specific panels for defined populations.…”

Section: When Should Effective Treatment Be Introduced Interrupted mentioning

confidence: 99%

Ovarian cancer treatment: The end of empiricism?

Lheureux

Karakasis

Kohn

et al. 2015

Cancer

View full text Add to dashboard Cite

The diagnosis, investigation, and management of ovarian cancer are in a state of flux—balancing ever rapid advances in our understanding of its biology with 3 decades of clinical trials. Clinical trials that started with empirically driven selections have evolved in an evidence‐informed manner to gradually improve outcome. Has this improved understanding of the biology and associated calls to action led to appropriate changes in therapy? In this review, the authors discuss incorporating emerging data on biology, combinations, dose, and scheduling of new and existing agents with patient preferences in the management of women with ovarian cancer. Cancer 2015;121:3203–3211. © 2015 American Cancer Society.

show abstract

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)

Cited by 29 publications

References 30 publications

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Factors in Oncogenesis: Viral Infections in Ovarian Cancer

Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer

Ovarian cancer treatment: The end of empiricism?

Contact Info

Product

Resources

About